|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.190 USD | -1.65% |
|
-10.53% | -28.74% |
| 05-13 | Lineage Cell Therapeutics, Inc., Q1 2026 Earnings Call, May 12, 2026 | |
| 05-12 | Lineage Cell Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Business description: Lineage Cell Therapeutics, Inc.
Number of employees: 75
Sales by Activity: Lineage Cell Therapeutics, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Research and Development of Therapeutic Products | 4.34M | 14.7M | 8.94M | 9.5M | 14.56M |
Geographical breakdown of sales: Lineage Cell Therapeutics, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 3.9M | 14.7M | 8.94M | 9.5M | 14.56M |
Foreign | 446K | - | - | - | - |
Executive Committee: Lineage Cell Therapeutics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Brian Culley
CEO | Chief Executive Officer | 54 | 16/09/2018 |
Jill Howe
DFI | Director of Finance/CFO | 50 | 13/11/2022 |
| Chief Operating Officer | - | 30/11/2010 | |
Ioana C. Hone
IRC | Investor Relations Contact | - | - |
| Corporate Officer/Principal | - | 31/03/2024 |
Composition of the Board of Directors: Lineage Cell Therapeutics, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Neal Bradsher
BRD | Director/Board Member | 60 | 30/06/2009 |
Deborah Andrews
BRD | Director/Board Member | 68 | 10/04/2014 |
Michael Mulroy
CHM | Chairman | 60 | 26/04/2024 |
Angus Russell
BRD | Director/Board Member | 70 | 08/12/2014 |
Brian Culley
BRD | Director/Board Member | 54 | 16/09/2018 |
Dipti Amin
BRD | Director/Board Member | 62 | 19/04/2021 |
| Director/Board Member | 69 | 03/05/2021 |
Company details: Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc.
2173 Salk Avenue
92008-7354, Carlsbad
+442 287 8990
http://www.lineagecell.com
Other Biotechnology & Medical Research
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.65% | -10.53% | +76.24% | -11.85% | 297M | |
| -1.81% | -3.85% | -17.26% | -17.46% | 42.68B | |
| -4.15% | -5.24% | +263.18% | +454.55% | 31.73B | |
| -1.84% | +0.68% | +20.44% | -12.04% | 30.62B | |
| -3.51% | -6.19% | +5.57% | +20.37% | 30.03B | |
| -2.89% | -6.70% | +14.76% | +15.33% | 24.25B | |
| -1.23% | +3.59% | +9.46% | +4.30% | 13.17B | |
| -3.83% | -6.10% | - | - | 13.07B | |
| -0.97% | +1.60% | +53.20% | +104.39% | 12.97B | |
| -0.87% | -2.64% | +111.05% | +83.67% | 12.31B | |
| Average | -2.29% | -3.41% | +59.63% | +71.25% | 21.11B | |
| Weighted average by Cap. | -2.53% | -3.14% | +55.38% | +84.46% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- LCTX Stock
- Company Lineage Cell Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition